Dramatic Reduction in Corneal Transplants for Keratoconus 15 Years After the Introduction of Corneal Collagen Crosslinking.

Purpose: The aim of this study was to investigate the effect of the implementation of corneal collagen crosslinking (CXL) on the frequency of corneal transplants among patients with keratoconus (KC) in the same region.

Methods: Before the introduction of CXL in 2007, 55 primary corneal transplants had been conducted in patients with KC (2005 and 2006) at the Department of Ophthalmology, Oslo University Hospital, Norway. We collected data from our corneal transplant registry for 2021 and 2022.

Prevalence and incidence of keratoconus in Norway: a nationwide register study.

Purpose: To estimate the national prevalence and incidence of keratoconus in Norway.

Methods: In this epidemiologic study, data were obtained from the Norwegian Patient Registry, which provides information from all publicly funded specialist care in Norway. Prevalence of keratoconus was estimated from the total number of patients registered with this diagnosis and incidence from the annual frequency of first-time registrations of patients up to 40 years of age in the period 2010-2018.

Randomized Study of Collagen Cross-Linking With Conventional Versus Accelerated UVA Irradiation Using Riboflavin With Hydroxypropyl Methylcellulose: Two-Year Results.

Purpose: To compare the clinical outcome 2 years after corneal collagen cross-linking (CXL) with conventional and accelerated ultraviolet A (UVA) irradiation using riboflavin with hydroxypropyl methylcellulose.

Methods: Prospective randomized controlled study. Forty patients with keratoconus (40 eyes) were randomized to either CXL using conventional 3 mW/cm UVA irradiation for 30 minutes (CXL30 group) or accelerated 9 mW/cm UVA irradiation for 10 minutes (CXL10 group).

Superior outcome of corneal collagen cross-linking using riboflavin with methylcellulose than riboflavin with dextran as the main supplement.

Purpose: To compare the effect of corneal collagen cross-linking (CXL) on progressive keratoconus using 0.1% riboflavin with either dextran or methylcellulose as the main supplement.

Methods: In a comparative case series, CXL was performed in 40 patients (40 eyes) using a riboflavin solution containing either dextran (dextran-riboflavin; n = 20) or methylcellulose (methylcellulose-riboflavin; n = 20).

Collagen crosslinking with conventional and accelerated ultraviolet-A irradiation using riboflavin with hydroxypropyl methylcellulose.

Purpose: To evaluate corneal collagen crosslinking (CXL) with conventional and accelerated ultraviolet-A (UVA) irradiation using riboflavin with methylcellulose.

Setting: Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.

Design: Prospective randomized case series.

Measuring the depth of crosslinking demarcation line in vivo: Comparison of methods and devices.

Purpose: To assess the interrelationship of different methods of measuring the demarcation line depth after corneal collagen crosslinking (CXL).

Setting: University eye clinic, Oslo, Norway.

Design: Prospective case series.

Does Corneal Collagen Cross-linking Reduce the Need for Keratoplasties in Patients With Keratoconus?

Purpose: To investigate whether the introduction of corneal collagen cross-linking (CXL) influences the frequency of keratoplasties in patients with keratoconus.

Methods: Data were obtained from a cohort of patients from our corneal transplant registry. Two different periods were compared, 2005 to 2006 (period 1) and 2013 to 2014 (period 2).

Corneal collagen crosslinking in vitro: inhibited regeneration of human limbal epithelial cells after riboflavin-ultraviolet-A exposure.

Purpose: To assess the hypothesis that during corneal crosslinking (CXL) treatment, riboflavin and ultraviolet-A (UVA) may have a toxic effect on human limbal epithelial cells.

Setting: Center for Eye Research, Department of Ophthalmology, Oslo University Hospital Ullevål, Oslo, Norway.

Design: Experimental study.